Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belzutifan + Lenvatinib vs Cabozantinib in Advanced RCC After Anti–PD-1/L1
jRCT2031210311Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Oct 2021
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial in clear cell renal cell carcinoma (ccRCC) comparing Belzutifan + Lenvatinib with Cabozantinib (2 arms). Primary endpoints: Progression-free survival and Overall survival. Started Oct 2021; status: active, not recruiting.
02
Drugs
belzutifanlenvatinibcabozantinib
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on jRCT2031210311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210311.